#FDA — FinScans

News 📈 Stocks

Scholar Rock Shares Jump 9% Following FDA Approval of ISEMBYLD

September 14, 2026 (57 days ago)

Scholar Rock rallies 9% as FDA approval of its muscle-targeted therapy for spinal muscular atrophy prompts a wave of analyst price target…

SRRK SPX DJI +1

🌍 AMERICAS Read More →

News 🌐 Macro

Trump's Tariff Threat Could Trigger US Generic Drug Shortages, Hitting Pharma Stocks

July 23, 2026 (110 days ago)

Trump’s tariff threat on pharmaceutical imports raises fears of generic drug shortages, hitting pharma stocks and potentially strengthening the US dollar amid…

TEVA DXY

🌍 US Read More →

News 📈 Stocks

Galderma Shares Plunge After FDA Rejects Botox Rival Relfydess

July 1, 2026 (132 days ago)

Galderma shares sank after the FDA rejected its Botox rival Relfydess, delaying U.S. market entry and strengthening AbbVie's grip on the aesthetics…

GALD ABBV

🌍 CH Read More →

News 📈 Stocks

UniQure Soars as FDA Clears Huntington’s Therapy for US Filing

June 17, 2026 (146 days ago)

UniQure stock pops following FDA’s reversal allowing Huntington’s disease therapy AMT-130 to move toward US approval filing.

QURE

🌍 US Read More →

News 📊 ETF IBB 📉 Bearish

Trump’s FDA Commissioner Is Resigning With Agency in Turmoil

May 12, 2026 (182 days ago)

FDA Commissioner Marty Makary’s resignation throws the agency into turmoil, threatening drug approvals and pressuring biotech and healthcare stocks.

▼ FDA Commissioner Makary resigns

📅 Short 🌍 US Read More →

News 📈 Stocks XLV 📉 Bearish

Clashes, Turmoil and Paranoia: Inside Trump’s FDA

May 8, 2026 (186 days ago)

FDA gridlock clouds drug approval timelines, pressuring healthcare stocks and ETFs like XLV and IBB.

▼ Escalating reports of FDA dysfunction deepen sector uncertainty.

📅 Short 🌍 US Read More →